Drug intelligence / Profile preview

Lefrex

Development stage
Unknown
Lead developer
SBM Enterprises
Modality
Small Molecules
Administration
Oral
01

Overview

Lefrex is a branded generic antibiotic containing levofloxacin, a third-generation fluoroquinolone. Marketed by SBM Enterprises (also known as SBM Pharmaceuticals) in India, it is typically available as a 500 mg oral tablet. Levofloxacin is a broad-spectrum antibacterial agent that works by inhibiting the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are critical for bacterial DNA replication, transcription, repair, and recombination; their inhibition leads to bacterial cell death. Lefrex is indicated for the treatment of various bacterial infections, including community-acquired pneumonia, urinary tract infections, skin and soft tissue infections, and infections of the ear, nose, and throat.

Brand names
LefrexLefrex-500Lefrex500Lefrex 500
Other names
levofloxacin
02

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on Lefrex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lefrex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call